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Abstract
Mitochondrial dysfunction is associated with various forms of lung
injury and disease that also involve alterations in pulmonary endothelial
permeability, but the relationship, if any, between the two is not well
understood. This question was addressed by perfusing the isolated intact rat
lung with a buffered physiological saline solution in the absence or presence
of the mitochondrial complex I inhibitor rotenone (20 uM). As compared to
control, rotenone depressed whole lung tissue ATP from 5.66 ± 0.46 (SEM) to
2.34 ± 0.15 (SEM) μmol·gram−1 dry lung, with concomitant increases in the
ADP:ATP and AMP:ATP ratios. Rotenone also increased lung perfusate lactate
(from 12.36 ± 1.64 (SEM) to 38.62 ± 3.14 μmol·15 min−1 perfusion·gm−1 dry
lung) and the lactate:pyruvate ratio, but had no detectable impact on lung
tissue GSH:GSSG redox status. The amphipathic quinone, coenzyme Q1
(CoQ1; 50 μM) mitigated the impact of rotenone on the adenine nucleotide
balance, wherein mitigation was blocked by NAD(P)H:quinone oxidoreductase
1 (NQO1) or mitochondrial complex III inhibitors. In separate studies,
rotenone increased the pulmonary vascular endothelial filtration coefficient
(Kf) from 0.043 ± 0.010 (SEM) to 0.156 ± 0.037 (SEM) ml·min−1·cm
H2O−1·gm−1 dry lung weight, and CoQ1 protected against the effect of
rotenone on Kf. A second complex I inhibitor, piericidin A, qualitatively
reproduced the impact of rotenone on Kf and the lactate/pyruvate ratio.
Taken together, the observations imply that pulmonary endothelial barrier
integrity depends on mitochondrial bioenergetics as reflected in lung tissue
ATP levels and that compensatory activation of whole lung glycolysis cannot
protect against pulmonary endothelial hyperpermeability in response to
mitochondrial blockade. The study further suggests that low molecular weight
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amphipathic quinones may have therapeutic utility in protecting lung barrier
function in mitochondrial insufficiency.

Keywords: Pulmonary endothelial permeability, pulmonary endothelium,
quinone, mitochondrial electron transport complex I, perfused lung,
pulmonary endothelial filtration coefficient (Kf)

Introduction
Studies in the isolated perfused lung have revealed that ~80 –
85% of total lung ATP is derived from mitochondrial respiration [1].
Pro-oxidant and other pathophysiological stresses target components
of lung mitochondria, including mitochondrial DNA (mtDNA) itself,
mitochondrial complex I and other complexes, and the tricarboxylic
acid cycle enzyme aconitase [2-6]. Mitochondrial bioenergetic
dysfunction arising from these and other lesions has been implicated in
various forms of clinical and experimental lung injury [7-16]. While
mitochondrial dysfunction is an all-purpose term for a panoply of
possible adverse effects on mitochondrial respiration and other
mitochondrial functions, a key readout, that may also underlie certain
manifestations of lung injury, is impairment of ATP generating capacity
[9, 16-21].
Acute lung injury is characterized by increased permeability of
the pulmonary endothelial barrier followed by accumulation of proteinenriched fluid in the airspaces and interstitium and impairment of gas
exchange [22]. Yet studies manipulating lung mitochondrial
bioenergetics as a means to discern its contribution to pulmonary
endothelial function have focused primarily on metabolic rather than
barrier function, with pulmonary edema used mostly as a toxicity
endpoint [23, 24]. The latter studies also involved nearly complete
dissipation of mitochondrial ATP generation, e.g., blockade of the
terminal chain component, cytochrome oxidase, or use of
mitochondrial electron transport uncouplers, and thus did not address
a perhaps more likely pathophysiological scenario involving partial
impairment at upstream mitochondrial targets. For example,
mitochondrial complex I activity is depressed by ~60% in lungs of rats
breathing elevated O2 (85% O2 for 48 hrs) compared to those in room
air, with no detectable effects on complexes III or IV [2]. While the
functional impact of the effect on complex I activity was not
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specifically investigated, there was no discernible pulmonary edema
resulting from the hyperoxic exposure, as reflected in lung wet-to-dry
weight ratios [2]. On the other hand, in rabbits exposed to 100% O2
for 48 hours, while there was also little change in lung water or arterial
blood gases in the intact animal, the pulmonary endothelial filtration
coefficient (Kf) increased, portending compromised endothelial barrier
integrity [25]. Thus, we asked whether there could be a link between
mitochondrial complex I activity blockade, mitochondrial function
reflected as diminished ATP generation and pulmonary endothelial
barrier function.
To address this question, acute exposure to the classical
complex I inhibitor, rotenone, was used to induce complex I blockade
in the perfused rat lung [26]. Rotenone was selected because our
previous studies in this preparation revealed that it caused nearly
complete blockade of complex I and depression of whole lung oxygen
consumption with no detectable impact on complexes III and IV [2,
27]. To determine the impact of rotenone on lung ATP levels and
energy charge, lung tissue adenine nucleotides (ATP, ADP and AMP)
were measured. Measurements of lung lactate and pyruvate efflux
were also included to evaluate glycolytic activity and lung tissue
cytosolic redox status. Finally, the rotenone effect on lung vascular
endothelial permeability was measured as the pulmonary endothelial
filtration coefficient (Kf) [22].
Complex I inhibition has the advantage in that it provides a
convenient model of the mitochondrial response in the hyperoxiaexposed rat lung, wherein downstream electron transport complexes
remain open as electron acceptors [2]. This allows for the possibility of
restoration of mitochondrial electron transport given the appropriate
electron donor or substrate. One possible donor is exemplified by low
molecular weight amphipathic hydroquinones that shuttle reducing
equivalents from cytosolic NAD(P)H to complex III, effecting a socalled bypass of a complex I block (Scheme 1) [28-30]. This is
proposed as a mechanism underlying the therapeutic effect of
quinones in treatment of neurological and other diseases arising from
mitochondrial genetic disorders, in experimental complex I dysfunction
or coenzyme Q10 deficiencies in other organs and cell types [28-32].
However, quinones as substrates for reactivation of mitochondrial
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electron transport and restoration of mitochondria-dependent lung
function have not been considered.

Scheme 1 Quinone-mediated mitochondrial electron transport complex I
bypass
A. The mitochondrial electron transport chain under physiological conditions, where
C(I), C(III), C(IV) and C(V) represent complexes I, III, IV and V, and with the
physiological quinone electron acceptor, CoQ10, and its reduced form, CoQ10H2. B.
Rotenone inhibits electron transport at C(1), blocking transfer of electron to CoQ 10 and
thus to C(III), preventing generation of the proton gradient across the mitochondrial
inner membrane, depolarizing the mitochondrial membrane potential (ΔΨ m) and
depressing ATP production. Compensatory activation of glycolysis increases lung
lactate generation as a reflection of increased cytosolic NADH levels. C. When the
exogenous amphipathic quinone (Q1) is present, it freely enters the lung tissue, where
it is reduced via cytosolic NQO1 at the expense of the endogenous electron donor,
NAD(P)H. The reduced hydroquinone form, Q1H2, enters the mitochondria and
transfers the reducing equivalents gained in the cytosol to C(III), thereby restoring
mitochondrial electron transport, proton pumping, ΔΨm and ATP generation. The
reoxidized quinone (Q1) returns to the cytosol to repeat the cycle. Thus, the Q1-Q1H2
redox pair acts to shuttle electrons from cytosolic NAD(P)H to C(III).

CoQ1 was selected as the candidate quinone because we have
previously studied its redox metabolism on passage through the
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isolated perfused rat lung. CoQ1 freely diffuses from the perfusate into
the lung tissue and is reduced to its hydroquinone form (CoQ1H2) via
cytosolic NAD(P)H quinone oxidoreductase 1 (NQO1) [2]. The CoQ1H2
produced crosses the mitochondrial membrane to act as an electron
donor at mitochondrial electron transport complex III [2]. Thus, since
the CoQ1-CoQ1H2 redox pair undergoes all the steps that theoretically
would be needed to effect a complex I bypass in the isolated perfused
lung, we hypothesized that CoQ1 administration would restore
mitochondrial bioenergetics, exemplified as ATP generation, and
protect the pulmonary endothelial barrier from complex I blockade
induced hyperpermeability, should it occur.

Materials and Methods
Materials
2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4benzoquinone (coenzyme Q1, hereafter referred to as CoQ1) was
purchased from Sigma. Bovine serum albumin (BSA) was purchased
from Equitech-Bio Inc. Lactate and pyruvate assay kits were obtained
from BioVision. All other chemicals, unless otherwise noted, were
purchased from Sigma.

Animals
Male Sprague-Dawley rats (Charles River) were housed in room
air with free access to food and water. The animal protocol was
approved by the Institutional Animal Care and Use Committee (IACUC)
of the Zablocki VAMC, Milwaukee, WI USA 53295.

Isolated perfused lung
Rats were anesthetized with pentobarbital sodium (40 mg/kg
body wt. i.p.), the chest opened and heparin (0.7 IU/g body wt.)
injected into the right ventricle. The lung and heart were removed
from the chest en bloc and suspended from a ventilation-perfusion
system without (n = 36) or with (n = 39) a calibrated force transducer
in place. The lung was ventilated (40 breaths per minute) with a gas
mixture containing 15% O2, 6% CO2, balance N2, with end-inspiratory
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and end-expiratory pressures of 8 and 3 cm H2O, respectively. The
lung was perfused (0.03 ml·min−1·gram−1 body weight) with a
physiologic salt solution containing (in mM) 4.7 KCl, 2.51 CaCl2, 1.19
MgSO4, 2.5 KH2PO4, 118 NaCl, 25 NaHCO3, 5.5 glucose and 5% bovine
serum albumin. The perfusate was maintained at 37°C and
equilibrated with the same gas mixture used for ventilation, resulting
in perfusate PO2, PCO2 and pH of ~105 Torr, 40 Torr and 7.4,
respectively. An initial volume of perfusate (~40 ml) was flushed
through the lung and discarded, after which time the lung was
perfused from a recirculating reservoir containing fresh perfusate.
During the initial 10 minutes of recirculation, the venous effluent
pressure (Pv) was held at atmospheric pressure, allowing time for the
pulmonary arterial pressure (Pa) to stabilize. Pa was referenced to
atmospheric pressure at the level of the left atrium and monitored
continuously during the course of the experiment.
Following the 10 minute stabilization period, the perfused lungs
entered one of two protocols, each described below. In the first
protocol, lungs were flash frozen in liquid N2 for measurements of
adenine nucleotides and oxidized (GSSG) and reduced (GSH) forms of
glutathione. In the second protocol, pulmonary endothelial
permeability was measured as the pulmonary endothelial filtration
coefficient (Kf) [22]. In both protocols, samples of pulmonary venous
effluent were collected and flash frozen in liquid N2 for measurements
of perfusate lactate and pyruvate levels. All biochemical
measurements were normalized to one gram of dry lung weight.

Protocol 1: Lung Adenine Nucleotides, GSH and GSSG
Following a 10 minute stabilization period of lung perfusion, the
perfusion pump was briefly halted, the reservoir emptied and refilled
with 35 ml fresh perfusate containing vehicle only, rotenone (20 M),
rotenone + CoQ1 (50 μM), CoQ1 alone (50 μM), rotenone + CoQ1 +
dicumarol (400 μM), or rotenone + CoQ1 + antimycin A (3.6 μM). We
have previously shown that at these concentrations, rotenone and
CoQ1 do not cause any detectable changes in lung hemodynamics or
wet:dry weight ratios [2].
The pump was restarted and the first 10 ml of pulmonary
venous effluent was discarded, after which the remaining perfusate
Free Radical Biology and Medicine, Vol. 65 (December 2013): pg. 1455-1463. DOI. This article is © Elsevier and permission
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

7

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

was recirculated through the pulmonary circulation for 15 minutes.
After 15 minutes, a 1 ml perfusate sample was collected from the
reservoir, flash frozen in liquid N2 and stored at −80°C for
measurement of lactate and pyruvate. Perfusion was halted, the lung
quickly cut away from the heart and connective tissue, weighed, flash
frozen in liquid N2, lyophilized to a constant weight, reweighed and
ground to a powder, which was dispensed into weighed samples of
~25 mg for storage at −80°C.
Adenine nucleotides were extracted from the lung powder
samples by addition of 5% perchloric acid (750 μl) followed by
centrifugation (10,000 × g, 5 min, 4°C) and neutralization of 500 μl of
supernatant with 400 μl K2HPO4 (1M). Sixty (60) μl of the extract was
mixed with 75 μl of potassium phosphate buffer (64.35 mM, pH 6.0)
containing 2.57 mM tetrabutylammonium hydrogen sulfate (2.57 mM),
the latter solution being the initial HPLC mobile phase. The solution
was filtered through a Nalgene 0.2 μm pore size cellulose acetate
syringe filter (Nalge Nunc International, Rochester, NY) prior to
injection onto the HPLC system. The HPLC system and mobile phase
were as previously described, with the difference being substitution of
a Phenomenex Kenetix C18 column (2.6 μm particle size, 100 × 4.6
mm) [33].
The adenine nucleotides were quantified against standards
prepared for each experiment, and the values normalized to 1 gm dry
lung powder, based on the weights of the individual lung powder
fractions used for each individual extraction. The adenylate energy
charge was then calculated as = (ATP + ½ ADP)/(ATP + ADP + AMP)
[34, 35].
GSSG and GSH glutathione were extracted from the lung
powder samples by addition of 2.5% ice cold sulfosalicylic acid
containing 0.2% Triton X-100 (final concentration of lung powder, 13.5
mg per ml extraction solution). The extraction mixture was centrifuged
(10,000 × g for 5 min at 4°C) and the resulting supernatant diluted
1:10 in 0.1 M sodium phosphate buffer (pH = 7.4) for determination of
GSSG and GSH, using the 5,5′-dithio-bis-(2-nitrobenzoic acid)-GSSG
reductase recycling assay [36-38].

Protocol 2: Pulmonary Endothelial Permeability (Kf)
Free Radical Biology and Medicine, Vol. 65 (December 2013): pg. 1455-1463. DOI. This article is © Elsevier and permission
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

8

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

The perfused lungs were suspended from a calibrated force
displacement transducer (Model FT03, Grass Instruments) and lung
weight was monitored continuously. Following a 10 min stabilization
period with Pv set at atmospheric pressure, the perfusate pump was
stopped. The reservoir was emptied, then refilled with 35 ml fresh
perfusate containing vehicle only (control), the complex I inhibitor
rotenone (20 μM) or rotenone (20 μM) + CoQ1 (50 μM), or CoQ1 alone
(50 μM). Alternatively, the complex I inhibitor piericidin A (1 μM) was
used in place of rotenone. With the reservoir stirring continuously, the
pump was restarted, the first 10 ml of venous effluent was discarded,
and the remaining perfusate was recirculated through the pulmonary
circulation. After 10 min of recirculation Pv was raised to ~5 cm H2O
(zone III conditions) and the lung was perfused for 20 min. At the end
of the 20 min, 1 ml of perfusate was collected from the stirred
reservoir, flash frozen in liquid N2 and stored at −80°C for
measurements of lactate and pyruvate. Then, Pv was raised to ~13.5
cm H2O and perfusion continued for an additional 10 min. These step
changes in pressure were more than adequate to allow appropriate
measure of Kf [22].
Kf was determined by dividing the rate of weight gain measured
10 minutes after increasing Pv from 5 to 13.5 cm H2O by the change in
pulmonary capillary pressure (Pc), the latter estimated as (Pa + Pv)/2.
The rate of weight gain at Pv ≅ 13.5 cm H2O was corrected for any
nonisogravimetric weight gain during the Pv ≅ 5 cm H2O period. Kf was
normalized per 1 gram dry lung weight.

Statistics
A one- way ANOVA with multiple comparisons was carried out
by the Waller-Duncan k-ratio t test method using SAS 9.2. [39]. The
Waller-Duncan test is an adaptive test which uses a very conservative
(as large as the Bonferroni) critical value if the overall groups p value
is near 0.05 and a much smaller critical value (nearly Fisher’s critical
value) when the overall test is quite significant, thus showing that
there are many differences to detect. It provides more clarity and
power to detect differences between groups than methods that are
static in cutoff. In addition, since many of the variables have different
standard deviations in the groups, a log transformation of each data
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point was used to stabilize the variance – a key assumption for an
ANOVA. The results were then transformed back to the original scale.

Results
The effects of rotenone alone (20 M) or rotenone + CoQ1 (50
μM) on lung ATP, ADP and AMP content are shown in Table 1.
Rotenone depressed lung ATP content and elevated ADP and AMP.
When CoQ1 was also present (rotenone + CoQ1), ATP, ADP and AMP
levels were indistinguishable from those in the untreated control lungs,
demonstrating that CoQ1 prevented the rotenone-induced lung ATP
depletion and adenine nucleotide imbalance. In contrast, the effects of
rotenone on lung ATP, ADP and AMP could not be overcome by CoQ1
when inhibitors of NQO1 (dicumarol) or complex III (antimycin A)
were also present (Table 1). The requirement for active NQO1 and
complex III for maintenance of lung ATP is consistent with a CoQ1
mechanism involving complex I bypass, wherein CoQ1 is reduced to
CoQ1H2 by NQO1 and the CoQ1H2 produced is reoxidized at complex
III, as depicted in Scheme 1C.
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Treatment

n

ATP

ADP

AMP

ATP + ADP
+ AMP

Vehicle Control

7

5.66 ± 0.46

b

1.17 ± 0.14

b,c

0.31 ± 0.06

c

7.15 ± 0.33

b

Rotenone

8

2.34 ± 0.15

c

1.83 ± 0.09

a

1.73 ± 0.29

b

5.90 ± 0.37

c

Rotenone + CoQ1

7

5.38 ± 0.29

b

1.22 ± 0.07

b

0.30 ± 0.04

c

6.90 ± 0.35

b,c

CoQ1

4

7.72 ± 0.36

a

0.93 ± 0.05

c

0.14 ± 0.04

d

8.79 ± 0.34

a

Rotenone + CoQ1 +
Dicumarol

5

1.23 ± 0.09

e

1.58 ± 0.04

a

3.12 ± 0.22

a

5.93 ± 0.35

c

Rotenone + CoQ1 +
Antimycin
A

5

1.68 ± 0.05

d

1.58 ± 0.04

a

2.84 ± 0.30

a

6.10 ± 0.23

c

Table 1 Rat lung tissue adenine nucleotide content (μmol·gram−1 dry lung)
after 15 min of perfusion with the experimental treatments in Protocol 1
studies
The values are means ± SE. Statistical analysis was carried out using ANOVA, with
multiple comparisons made using the Waller-Duncan k-ratio t-test. Means with the
same letter designations are in the same group and not significantly different
(p>0.05). Means with two letters are not different from either group. Means with
different letter designations are in different groups and are significantly different from
each other (p<0.05).

Figures 1A - C show the lung ADP:ATP ratios, AMP:ATP ratios
and energy charges calculated from the Table 1 data, where energy
charge is defined as (ATP + ½ ADP)/(AMP + ADP + ATP). As compared
to control, rotenone increased the ADP:ATP and AMP:ATP ratios and
depressed the energy charge. When CoQ1 was present along with
rotenone, the ADP:ATP and AMP:ATP ratios and the energy charge
were not detectably different from controls. When the NQO1 or
complex III inhibitors, dicumarol or antimycin A, respectively, were
included with CoQ1 + rotenone, they blocked the ability of CoQ1 to
prevent the rotenone-induced disruption of adenine nucleotide
balance, as exemplified in Figures 1A - C.
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Figure 1 Rat lung tissue ADP/ATP ratios (A), AMP/ATP ratios (B) and
energy charges (C) after 15 min of perfusion with experimental treatments
The ratios and energy charges (mean ± SE) were calculated from the individual lung
data used to calculate the mean values in Table 1. Energy charge was calculated as
(ATP + ½ ADP)/(ATP + ADP + AMP). Statistics were carried out as described in Table
1, wherein means with the same letter designation are not significantly different from
each other (p<0.05); means with different letters are significantly different.

Figure 2 shows the fractional ATP, ADP or AMP concentrations vs
the energy charges calculated for each of the 36 individual lungs used
to obtain the mean values in Table 1. This representation emphasizes
the wide range in lung energy charges produced by the experimental
treatments. The solid lines represent the theoretically predicted
proportions of ATP:ADP:AMP at any given energy charge under the
assumption that the adenylate kinase reaction is a key factor
regulating the equilibrium levels [34, 35] (See Appendix).
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Figure 2 Lung tissue fractional concentrations of ATP, ADP and AMP vs
energy charge for the experimental treatments in Protocol 1 studies
The symbols are the fractional adenine nucleotide values calculated from individual
lung adenine nucleotide measurements that make up the mean values in Table 1 (n =
36). Energy charge was calculated as described in the Figure 1 legend. The solid lines
show the theoretical proportions of ATP, ADP and AMP present at the indicated energy
charge if the adenylate kinase equilibrium [ATP][AMP]/[ADP]2 = 1.2 was controlling
the relative amounts of the adenine nucleotides [35].

Table 2 shows the effects of the treatment conditions on lung
lactate and pyruvate production, and the total lactate + pyruvate
levels. As compared to control, rotenone increased lung lactate
generation with no detectable effect on pyruvate, suggesting activation
of glycolysis as a compensatory response to complex I blockade [40].
Then, as compared to rotenone alone, CoQ1 + rotenone decreased
lactate levels and increased pyruvate levels (Table 2), implying that
CoQ1 tends to dampen the impact of rotenone to activate glycolysis.
The increase in pyruvate is apparent for every Table 2 treatment
containing CoQ1. The effect of CoQ1 to mitigate the rotenone-induced
increase in glycolytic activity, as reflected by lactate levels, was
effectively blocked by dicumarol and antimycin A (Table 2). Figure 3
shows the negative correlation between lactate levels (i.e., glycolytic
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activity) and energy charge across the treatment groups, suggesting
that activation of glycolysis could not fully compensate for the energy
deficit induced by complex I blockade.

Figure 3 Lung perfusate lactate vs lung tissue energy charge in Protocol 1
studies
Each symbol represents the lactate level for an individual lung (from Tables 1 and
and2),2), plotted vs the energy charge calculated for the same lung. Pearson Product
Moment Correlation r = 0.837, p<0.01.
Treatment

n

Lactate

Pyruvate

Lactate +
Pyruvate

Vehicle Control

4

12.36 ± 1.64

c

0.88 ± 0.11

d

13.24 ± 1.66

c

Rotenone

4

38.62 ± 3.14

a

0.87 ± 0.14

d

39.49 ± 3.12

a

Rotenone + CoQ1

3

24.64 ± 1.96

b

2.58 ± 0.20

a

27.23 ± 1.92

b

CoQ1

4

14.77 ± 2.02

c

2.12 ± 0.18

a,b

16.90 ± 2.08

c

Rotenone + CoQ1 +
Dicumarol

4

34.31 ± 0.81

a

1.70 ± 0.26

b,c

36.01 ± 0.97

a

Rotenone + CoQ1 +
Antimycin A

4

34.63 ± 2.22

a

1.42 ± 0.06

c

36.05 ± 2.19

a
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Table 2 Lung lactate and pyruvate production over the 15 min treatment
periods (μmol ·15 min−1·gram−1 dry lung) in Protocol 1 studies
Measurements were made in pulmonary venous effluent samples of a subset of lungs
in Table 1. The values are means ± SE. Statistical analysis was carried out as
described in Table 1. Means with the same letter designation are in the same group
and not significantly different (p>0.05); means with different letter designations are in
different groups and significantly different from each other (p<0.05).

Figure 4 shows the effect of the treatment conditions on lung
tissue lactate and pyruvate levels expressed as the lactate/pyruvate
ratio, as an index of cytosolic NADH/NAD+ status. Rotenone
substantially increased the ratio as compared to control, and when
CoQ1 was added with rotenone, the ratio was normalized. However,
with CoQ1 alone, the ratio was actually lower than control, a reflection
of the general CoQ1 impact on pyruvate levels seen in Table 2. This
CoQ1 effect also comes into play when dicumarol or antimycin are
added, wherein we might expect either to more convincingly block the
mitigating effect of CoQ1 on the rotenone-induced increase in
lactate/pyruvate ratio. Table 3 shows that despite the large effect
rotenone had on the lactate/pyruvate ratio, it had no detectable
impact on whole lung glutathione redox status (GSH/GSSG).
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Figure 4 Lung perfusate lactate/pyruvate ratios produced by the
treatments in Protocol 1 studies
The lactate/pyruvate ratios (mean ± SE) were calculated from the individual lung
lactate and pyruvate data used to calculate the mean values in Table 2. Statistical
analysis was carried out as described in Table 1. Means with the same letter
designation are not significantly different (p>0.05); means with different letter
designations are significantly different from each other (p<0.05).

Treatment

n GSH

GSSG

GSH + GS

GSH/GSSG

Vehicle Control 7 10.71 ± 0.77 0.36 ± 0.05 11.44 ± 0.84 32.61 ± 4.40
Rotenone

8 9.73 ± 0.69

0.34 ± 0.03 10.35 ± 0.70 30.76 ± 3.94

Table 3 Lung tissue reduced (GSH) and oxidized (GSSG) glutathione after
15 min perfusion with rotenone (μmol·gram−1 dry lung) in Protocol 1 studies
Values are means ± SE. There were no statistically significant differences (t-test,
p>0.05).

Table 4 shows that there were no statistically significant effects
of Protocol 1 study conditions or treatments on lung wet-dry weight
ratios or pulmonary arterial perfusion pressures, and thus no
detectable overt, non-specific lung injury.
Treatment

n Body
Weight (g)

Lung Wet to Dry Pulmonary
Weight Ratio
Arterial Pressure
(cm H2O)

Vehicle Control

7 362.9 ± 27.6 5.87 ± 0.24

7.3 ± 0.9

Rotenone

8 362.4 ± 31.8 5.83 ± 0.13

6.8 ± 0.5

Rotenone + CoQ1

7 387.7 ± 41.6 5.67 ± 0.20

6.9 ± 0.7

CoQ1

4 322.0 ± 7.1

5.29 ± 0.07

6.6 ± 0.4

Rotenone + CoQ1 + Dicumarol 5 326.4 ± 6.4

5.88 ± 0.14

6.4 ± 0.3

Rotenone + CoQ1 + Antimycin 5 316.6 ± 3.4
A

5.55 ± 0.12

6.3 ± 0.7

Table 4 Body weights, lung wet:dry weight ratios and pulmonary arterial
(perfusion) pressures for Protocol 1 studies
Data are means ± SE. There were no statistically significant differences between
parameter values in the different study groups (p > 0.05).
The isolated perfused rat lung was treated with the complex I inhibitor rotenone.
Rotenone depressed lung ATP and energy charge with no detectable impact on
GSH:GSSG. Rotenone increased the pulmonary endothelial filtration coefficient (Kf).
Coenzyme Q1 largely prevented the effects of rotenone in the lung.
The CoQ1 mechanism was via complex I bypass and restoration of lung ATP
generation.
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Figure 5 shows the impact of rotenone on pulmonary endothelial
permeability, in the absence or presence of CoQ1, measured as Kf in
Protocol 2 studies. We note that conditions were met for accurate
estimation of Kf [22]: step changes in pressure were more than
adequate and the treatments had no detectable effects on
hemodynamic parameters (Pa, Pv, pulmonary vascular resistance or
pulmonary capillary pressure, data not shown). Kf was 3.6 fold higher
in rotenone-treated than control lungs (p < 0.05). CoQ1 prevented the
rotenone-induced increase in Kf, without having a detectable impact on
its own (Figure 5). Further, as shown in Figure 6, the Protocol 2 study
conditions used to determine Kf did not in and of themselves influence
the impact of the treatment conditions on lung cytosolic redox status,
as reflected in the lactate:pyruvate ratios, since these were reasonably
similar to those obtained in the Protocol 1 studies (Figure 4).

Figure 5 Effect of rotenone and CoQ1 on the filtration coefficient (Kf) in rat
lung in Protocol 2 studies
The bars represent the means ± SE for Kf measured in vehicle control (n = 13),
rotenone (n = 6), rotenone + CoQ1 (n = 6), or CoQ1 (n = 7) treated lungs. Means with
the same letter designation are not significantly different (p>0.05); means with
different letter designations are significantly different from each other (p<0.05).
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Figure 6 Lung perfusate lactate/pyruvate ratios in lungs undergoing Kf
procedure in Protocol 2 studies
The ratios (mean ± SE) obtained from Figure 5 studies, including vehicle control (n =
13), rotenone (n = 6), rotenone + CoQ1 (n = 6) and CoQ1 only (n = 7) treated lungs.
Statistical analysis was carried out as described in Table 1. Means with the same letter
designation are not significantly different (p>0.05); means with different letter
designations are significantly different from each other (p<0.05).

Finally, Figure 7 shows that an alternative complex I inhibitor,
piericidin A, produced qualitatively similar effects to rotenone on the Kf
and lactate:pyruvate ratios in Protocol 2 studies.
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Figure 7 Effect of the complex I inhibitor piericidin A on Kf and lung
perfusate lactate/pyruvate ratios in Protocol 2 studies
The bars represent the means ± SE for Kf measured in vehicle controls (n = 13) or
piericidin A (n = 7) treated lungs. * Significantly different from control (p<0.05; ttest).

Discussion
The study demonstrates that rotenone-induced blockade of
mitochondrial electron transport complex I in the isolated perfused rat
lung resulted in ATP depletion and depression of the adenylate energy
charge. Rotenone also increased perfusate lactate levels, the
lactate:pyruvate ratio, and pulmonary vascular endothelial
permeability, measured as Kf. A second complex I inhibitor, piericidin
A, qualitatively reproduced the impact of rotenone on Kf and the
lactate:pyruvate ratio.
The quinone CoQ1 largely prevented the impact of rotenone on
lung tissue ATP levels, energy charge and lactate production. The
ability of CoQ1 to prevent the effects of rotenone on these biochemical
parameters depended on both NQO1 and complex III activities. In
separate studies, CoQ1 also blocked the rotenone-induced increase in
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Kf. Under the assumption that this CoQ1 effect on Kf involves
restoration of mitochondrial bioenergetics, reflected as ATP generation,
and thus would also depend on NQO1 and complex III activities, the
study implicates a CoQ1 mechanism involving a cytosolic-mitochondrial
electron shuttle that bypasses complex I to restore mitochondrial
electron transport by transfer of electrons to complex III. This
sequence of quinone:hydroquinone redox reactions with restoration of
mitochondrial respiration in pharmacological or genetic complex I
dysfunction has been reported in the isolated perfused rat lung using
duroquinone, and by others in various cell and isolated mitochondrial
preparations using a range of quinones [26-29]. However, to our
knowledge, the present findings provide the first evidence showing
bioenergetic and functional protection afforded by a quinone in a
complex I activity-deficient intact organ preparation and implicating
complex I bypass as the mechanism,.
In our study, the read-out for blockade of mitochondrial electron
transport was ATP production and the adenylate energy charge. The
energy charge vs fractional ATP, ADP and AMP relationships shown in
Figure 2 suggest that the lung is a highly energized and metabolically
active organ, able to maintain a predictable ATP:ADP:AMP equilibrium
across a range of bioenergetic manipulations, consistent with previous
studies [1, 9, 41]. The solid lines in Figure 2 represent the
theoretically predicted proportions of ATP:ADP:AMP at any given
energy charge. This prediction is based on the assumption that the
adenylate kinase reaction is a key factor regulating the equilibrium
levels [34, 35] (see Appendix). Insofar as adenylate kinase has been
implicated as a key reaction regulating energy balance and ATP
availability under conditions of increased stress, represented here by
rotenone treatment, the close adherence of the data to the prediction
is consistent with the concept of this enzyme as such a regulatory
factor, and suggest that the treatments did not exert non-specific
effects on adenylate kinase and/or other components involved in this
process [42].
The impact of rotenone on lung perfusate lactate and pyruvate
levels implies that complex I blockade evoked a compensatory
increase in glycolytic activity, as in other lung studies using rotenone
or other mitochondrial inhibitors [1, 23, 40, 43]. Accordingly, the
rotenone effect on the lactate/pyruvate ratio is consistent with
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inhibition of mitochondrial electron transport [23]. Of course, like the
adenine nucleotide measurements, perfusate lactate and pyruvate
levels represent the whole lung. Whereas the relative contribution
arising from any given lung cell type or tissue compartment is
unknown, and even the relative contribution of mitochondrial vs
glycolytic energy production in the in situ pulmonary endothelium is
debated, we would expect that pulmonary endothelial cells contribute
substantially to the net effect based on their contribution to total lung
cell volume. Nevertheless, glycolysis could not fully compensate for
the adenylate energy imbalance caused by complex I blockade, nor
could it overcome the functional consequence of complex I blockade,
i.e., pulmonary endothelial hyperpermeability. This observation is
consistent with a previous study showing that glycolysis was not
required to maintain pulmonary endothelial-epithelial barrier function
in the perfused rabbit lung [40]. In contrast to the intact lung,
pulmonary endothelial cells in culture required simultaneous inhibition
of glycolytic and mitochondrial ATP generation to evoke a permeability
response [44]. The implication is that the relative contribution of
mitochondrial bioenergetic function to pulmonary endothelial barrier
integrity is more dominant in the intact lung than in cell culture
conditions.
Whereas CoQ1 prevented the rotenone-induced depression in
ATP, and tended to dampen the impact of rotenone on glycolysis (as
reflected in lactate levels), the elevated pyruvate generation whenever
CoQ1 was present suggests that it may have done so at the expense of
cytosolic NADH, as a source of reducing equivalents for reduction of
both CoQ1 and pyruvate, the latter via the lactate dehydrogenase
reaction. Then the CoQ1-induced effect on pyruvate could be explained
as competition for NADH. However, although we did not carry out a
flux analysis, the observation that the CoQ1-induced increases in
pyruvate account for only ~ 2 – 4% of the total lactate + pyruvate
suggests an additional or supplementary electron donor pathway for
CoQ1 reduction. Our previous observations implicate pentose
phosphate pathway generated NADPH, which we showed to be the
predominant source of reducing equivalents for NQO1-catalyzed
duroquinone reduction in pulmonary endothelial cells in culture [33].
We also demonstrated that the majority of CoQ1 reduction on passage
through the rat pulmonary circulation in the presence of rotenone is
via NQO1 [2]. Under the assumption that NADPH would also be a
Free Radical Biology and Medicine, Vol. 65 (December 2013): pg. 1455-1463. DOI. This article is © Elsevier and permission
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

21

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

dominant electron donor for NQO1-catalyzed CoQ1 reduction in the rat
lung, quinone activation of the pentose phosphate pathway would
generate the NADPH to reduce CoQ1 (via the oxidative branch) and
explain a CoQ1 effect to increase glycolytic intermediates (via the nonoxidative branch). Then the net result of CoQ1 would be enhanced ATP
generation via both mitochondrial and glycolytic pathways.
Inhibition of mitochondrial electron transport with rotenone or
piericidin A has been implicated in reactive oxygen species (ROS)
generation in some cell types and sub-cellular preparations [45-48].
However, in the lung and pulmonary endothelial cells, several reports
indicate that acute rotenone treatment actually suppresses ROS
generation induced by various stimuli, including elevated pulmonary
capillary pressure or hyperoxia [49-53]. We did not measure ROS
generation per se, but the rotenone treatment in the present study did
not deplete GSH or alter the GSH:GSSG ratio in whole lung tissue,
suggesting that if excessive ROS production occurred, it did not cause
global, overt oxidative stress. However, we acknowledge that the
GSH:GSSG ratio in total lung tissue may not reveal mild or
compartmentalized ROS generation that could initiate a focal Ca2+dependent hyperpermeability response [54]. In that case, CoQ1
mitigation of the rotenone-induced permeability response might be
attributed to the antioxidant activity of CoQ1H2. However, we do not
favor this interpretation, as it does not account for the observation
that complex III inhibition blocks the mitigating effect of CoQ1 on
adenine nucleotide balance under conditions in which CoQ1H2 would
continue to be generated via NQO1.
Another potential mechanism by which rotenone could impact
pulmonary endothelial permeability is via direct disruption of
microtubule assembly, wherein microtubules are an essential
cytoskeletal element influencing permeability of cultured endothelial
cell monolayers [55-58]. Whether rotenone is acting as a microtubule
disrupter in the present study was not evaluated. However, insofar as
CoQ1 protected against the impact of rotenone on Kf, and if anything,
certain other quinones cause microtubule disruption, a CoQ1
mechanism involving direct microtubule stabilization seems unlikely
[59].
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We have interpreted the data from the perspective that Kf
reflects primarily endothelial permeability in the isolated lung. This
interpretation must take into account the recognition of lung
endothelial heterogeneity, that is, the notion that endothelium in lung
extra-alveolar vessels and the alveolar septal compartment display
distinct metabolic and permeability-responsive phenotypes [60]. For
example, lung microvascular endothelial cells, at least in cell culture,
are more glycolytic than those derived from the pulmonary artery
[61]. The more glycolytic phenotype may confer a relative insensitivity
to mitochondrial blockade, relegating the increased permeability
response to the larger extra-alveolar vessels. Nevertheless, we found
that glycolysis, no matter how robust, failed to fully compensate for
the rotenone effects on energy charge or pulmonary endothelial
permeability.
A straightforward explanation of the rotenone-induced increase
in Kf is that disruption of mitochondrial bioenergetic function, reflected
as ATP depletion, impairs the pulmonary endothelial permeability
response, an effect mitigated by CoQ1. Several potential mechanisms
should be considered here. First, ATP could be required as the energy
source for repletion of intracellular Ca2+ stores that drive store
operated channel-mediated pulmonary endothelial permeability
responses [62]. If true, ATP depletion would preferentially impact
permeability in extra-alveolar vessels and lead to perivascular cuffing
rather than alveolar flooding. Yet we observed that lungs treated with
rotenone or piericidin A tended to develop frank alveolar flooding by
the end of the perfusion period. Second, viewing ATP depletion in a
broader sense, as a biomarker of mitochondrial dysfunction, other
possibilities arise, including impaired mitochondrial Ca2+ handling [6264]. While a role for mitochondrial Ca2+ has not been evaluated in the
context of pulmonary endothelial barrier function, it has been
implicated in transducing pressure-induced pro-inflammatory
responses in lung venular capillaries [53]. If mitochondrial Ca2+
signaling is a mechanism of pulmonary endothelial barrier dysfunction,
we predict that the effect would not be restricted to a specific lung
vascular compartment. Finally, Kf may also be influenced by depressed
activity of the alveolar epithelial Na+/K+-ATPase, wherein tight junction
structure and permeability are highly ATP-dependent in alveolar and
other epithelial cells [65-67]. However, while rotenone exposure
mimics the hyperoxia-induced decrease in complex I activity observed
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in rats breathing 85% O2 for 48 hours, exposure to the same sublethal oxygen tension, albeit for longer time courses, is associated with
increased trans-epithelial sodium transport, and thus increased
alveolar fluid clearance [68]. Further observations that alveolar
epithelial Na+2 transport can be supported by glycolysis in the
presence of mitochondrial inhibitors, including rotenone, has actually
led others to conjecture that the pulmonary endothelium is the site of
barrier failure in mitochondrial insufficiency [43]. In light of these
studies, the implication is that the pulmonary endothelium is also a
predominant site of the hyperoxia-induced increase in Kf observed in
the rabbit lung [25]. Nonetheless, our conclusion that complex I
bypass affords significant protection against rotenone-induced barrier
dysfunction in lung remains valid regardless of whether the
endothelium, epithelium or both provide the main target.

Conclusion
Mitochondrial bioenergetic dysfunction, reflected as ATP
depletion, and/or decreased activity of electron transport complexes or
other mitochondrial components have been reported in various forms
of experimental and clinical lung disease, including hyperoxia,
phosgene- or paraquat-induced lung injury, ischemia reperfusion
injury, in lung preservation for transplantation and in chronic
obstructive pulmonary disease [9, 16-21]. One aspect of such
dysfunction is a deficiency in movement of reducing equivalents
through the mitochondrial electron transport chain and ATP depletion.
Amphipathic CoQ10 homologs and analogs (e.g., CoQ1) restore
mitochondrial function and ATP generation by shuttling reducing
equivalents from the cytosol to the mitochondria [28-30, 32]. This
mechanism provides one basis for use of quinones in treating patients
with neurological and other disorders associated with genetic
mitochondrial deficiencies [31]. The present study demonstrates that
CoQ1 prevents energy charge depletion and pulmonary endothelial
hyperpermeability evoked by complex I blockade in the isolated
perfused rat lung, and provides evidence that the impact on energy
charge is via a cytosolic-mitochondrial electron shuttle. The implication
is that certain quinones may also be beneficial in protection of the lung
from pulmonary edema associated with acute lung injury, when the
injury involves mitochondrial dysfunction.
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Supplementary Material
Appendix:
Adenylate kinase catalyzes the following reaction:

Using mass action:

Then using algebraic manipulation of equations (1-2), one could show
that:

Thus, for a given EC and K values, equation (4) can used to determine
[ADP]. Knowing [ADP], then [ATP] and [AMP] are determined from
equation (2) and equation (3), respectively.
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